Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome

Lancet Diabetes Endocrinol. 2019 Jun;7(6):421-423. doi: 10.1016/S2213-8587(19)30072-5. Epub 2019 Mar 15.

Authors

Ana Luisa Perdigoto¹, Zoe Quandt², Mark Anderson², Kevan C Herold³

Affiliations

¹ Department of Internal Medicine, Yale University, New Haven, CT 06520, USA.
² Department of Internal Medicine, University of California at San Francisco, San Francisco, CA, USA.
³ Department of Internal Medicine, Yale University, New Haven, CT 06520, USA; Department of Immunobiology, Yale University, New Haven, CT 06520, USA. Electronic address: kevan.herold@yale.edu.

PMID: 30885563
DOI: 10.1016/S2213-8587(19)30072-5

No abstract available

MeSH terms

Antineoplastic Agents, Immunological / adverse effects*
Diabetes Mellitus, Type 1 / chemically induced*
Diabetes Mellitus, Type 1 / immunology
HLA-DR4 Antigen
Humans

Substances

Antineoplastic Agents, Immunological
HLA-DR4 Antigen